Emergent BioSolutions Inc.

NYSE:EBS Voorraadrapport

Marktkapitalisatie: US$492.7m

Emergent BioSolutions Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Emergent BioSolutions's earnings have been declining at an average annual rate of -61.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 0.9% per year.

Belangrijke informatie

-61.4%

Groei van de winst

-61.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-0.9%
Rendement op eigen vermogen-152.0%
Nettomarge-53.3%
Volgende winstupdate06 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Oct 04

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Jul 15

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

May 10

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Opbrengsten en kosten

Hoe Emergent BioSolutions geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NYSE:EBS Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241,102-5873430
31 Mar 241,185-5653570
31 Dec 231,049-7603680
30 Sep 231,103-7783670
30 Jun 231,072-6023630
31 Mar 23974-3943510
31 Dec 221,118-2123400
30 Sep 221,491333410
30 Jun 221,581883410
31 Mar 221,7571583520
31 Dec 211,7742203490
30 Sep 211,6532273360
30 Jun 211,7092993300
31 Mar 211,7063873150
31 Dec 201,5773063040
30 Sep 201,3331672890
30 Jun 201,2591702780
31 Mar 201,108682730
31 Dec 191,106552740
30 Sep 191,01642780
30 Jun 19878-182550
31 Mar 19855422230
31 Dec 18782632030
30 Sep 187061001630
30 Jun 186811131560
31 Mar 18562671480
31 Dec 17561831430
30 Sep 17519811310
30 Jun 17512681330
31 Mar 17503611370
31 Dec 16489631430
30 Sep 16497731390
30 Jun 16512941280
31 Mar 165291251190
31 Dec 15489911210
30 Sep 15478791100
30 Jun 15457591150
31 Mar 15460351190
31 Dec 14404541090
30 Sep 14400221090
30 Jun 14351141010
31 Mar 1432419910
31 Dec 1331331850

Kwaliteitswinsten: EBS is currently unprofitable.

Groeiende winstmarge: EBS is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: EBS is unprofitable, and losses have increased over the past 5 years at a rate of 61.4% per year.

Versnelling van de groei: Unable to compare EBS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: EBS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: EBS has a negative Return on Equity (-151.95%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden